此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Promoting Equity for Cancer Screening and Follow-up

2021年10月19日 更新者:Chyke A. Doubeni、Mayo Clinic

Promoting Equity Through Multicomponent Strategies for Cancer Screening and Follow-up (PREMiS)

This is a randomized trial to assess the efficacy of reminder mechanisms on colorectal cancer (CRC) screening uptake among a cohort of patients who were previously mailed a multitarget stool DNA (mt-sDNA) test and did not complete the screening. Patients will be identified as being due for CRC screening and will be mailed a mt-sDNA kit to their home. Patients who do not complete screening with mt-sDNA within 30 days will be identified and randomized into one of three study arms to receive reminders to complete the mt-sDNA screening. The primary outcome is the rate of completion of screening for colorectal cancer with mt-sDNA test.

研究概览

详细说明

Colorectal cancer (CRC) is the third leading cause of cancer-related death in the United States, and screening has been shown to reduce mortality from CRC. Screening is underutilized in the United States, particularly in some communities such as Blacks/African Americans, American Indians/Alaskan Natives, and rural populations, contributing to disparities in mortality.

For CRC screening, mt-sDNA testing is one of several tests that are recommended by the United States Preventive Services Task Force (USPSTF). As part of a quality improvement program at our institution, those who are due for CRC screening are identified using a validated electronic algorithm and a kit is mailed directly to each patient. Our intervention is initiated on non-respondents to the mailed mt-sDNA outreach by testing the use of a technology-enabled reminder system.

Thirty days after being mailed a mt-sDNA kit, patients who have not completed the screening will be randomized to receive a reminder to complete the mt-sDNA screening by one of three mechanisms (time 0):

  1. Automated reminder using the EHR patient portal messaging system.
  2. Automated reminder using a customized interactive voice response (IVR) system
  3. Personalized reminder phone calls from the clinical team

This will allow for an empirical test of processes that can be employed to improve delivery of CRC screening and reduce preventable deaths in populations that are underserved with evidence-based interventions.

研究类型

介入性

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Minnesota
      • Rochester、Minnesota、美国、55905
        • Mayo Clinic in Rochester

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

50年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Adults, between 50 to 75 years old.
  • Due for colorectal cancer screening based on not having a record of a colonoscopy within 10 years, sigmoidoscopy, or CT colonography within 5 years, mt-sDNA within 3 years, or FIT within 1 year.
  • Asymptomatic for colorectal cancer such as rectal bleeding or reported abdominal mass.

Exclusion Criteria:

  • For the intervention study, patients will be restricted to those aged 50 to 75 years and are due for colorectal cancer screening.
  • We will exclude any patient who has:
  • Had prior colonoscopy within 10 years, sigmoidoscopy within 5 years, mt-sDNA within 3 years, CT colonography within 5 years, and FOBT/FIT within twelve months of inclusion into the study;
  • A diagnosis of CRC or other GI cancer;
  • History of confirmed Inflammatory Bowel Disease (Crohn's disease, ulcerative colitis) or other colitis;
  • Had a colectomy, partial or total;
  • A diagnosis of Lynch Syndrome;
  • A diagnosis of Familial Adenomatous Polyposis (FAP);
  • Iron deficiency anemia;
  • Lower GI bleeding;
  • A metastatic (Stage IV) blood or solid tumor cancer;
  • End stage renal disease;
  • A first degree relative with CRC prior to age 50 or 2+ first degree relatives diagnosed at any age.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:卫生服务研究
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:IVR Reminder
Participants will receive an interactive voice reminder
Participants will receive an interactive voice reminder (IVR) to complete mt-sDNA screening at day 7 and 21.
有源比较器:Personalized Phone Call Reminder
Participants will receive a personalized phone call
Patients will receive a scripted phone call from the research team to remind them to complete the mt-sDNA screening at day 7 and 21.
有源比较器:Portal Message Only
Participants will receive a online patient portal message reminder
Patients will receive an EHR patient portal message with a scripted message to remind them to complete the mt-sDNA screening at day 7 and 21.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Primary Endpoint (intention-to-treat)
大体时间:Completion by 6 months post randomization
The completion rate of mt-sDNA among eligible patients. The primary comparison will be the return rate compared across intervention arms.
Completion by 6 months post randomization

次要结果测量

结果测量
措施说明
大体时间
Secondary Outcome (per protocol analysis)
大体时间:Completion by 6 months post randomization
The completion rate of mt-sDNA among eligible patients. The comparison will be the return rate compared across intervention arms, excluding participants who received an alternative intervention due to not having appropriate portal access.
Completion by 6 months post randomization

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Chyke Doubeni, MBBS, MPH、Mayo Clinic

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (预期的)

2021年9月1日

初级完成 (预期的)

2023年5月1日

研究完成 (预期的)

2023年5月1日

研究注册日期

首次提交

2021年4月1日

首先提交符合 QC 标准的

2021年4月1日

首次发布 (实际的)

2021年4月5日

研究记录更新

最后更新发布 (实际的)

2021年10月27日

上次提交的符合 QC 标准的更新

2021年10月19日

最后验证

2021年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅